OIS Investor Perspectives Panel with Jeffry Weinhuff, Visionary Managing Partner, along with KKR, NEA, OrbiMed, & HIG

News, Visionary

Ophthalmology Innovation Summit Year in Review – Investor Perspectives

Participants:
Arjun Arora, Director – KKR
Ali Behbahani, MD, General Partner – NEA
Anat Naschitz, Managing Director – OrbiMed
Bruce Robertson, Managing Director – H.I.G. Capital
Jeffry Weinhuff, Managing Partner – Visionary Venture Fund

Moderated By:
William J. Link, PhD, Managing Partner – Flying L Partners

Orasis Closes $30MM Series C Round for Phase III Trials and Pre-Commercialization Activities.

News, Orasis

Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing an innovative pharmaceutical solution for the treatment of presbyopia symptoms, today announced the initiation of NEAR-1 and NEAR-2 Phase 3 clinical studies in the U.S., evaluating its novel eye drop candidate designed to improve near vision for people with presbyopia.

Tarsus Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Full Exercise by the Underwriters of Option to Purchase Additional Shares

IPO, News, Tarsus

Tarsus Pharmaceuticals, Inc. (“Tarsus”), a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities initially in ophthalmic conditions, today announced the closing of its initial public offering of 6,325,000 shares of its common stock at a price to the public of $16.00 per share, which includes 825,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares of common stock. All of the shares were offered by Tarsus. The aggregate gross proceeds to Tarsus from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately $101.2 million.

Orasis Closes $30MM Series C Round for Phase III Trials and Pre-Commercialization Activities.

News, Orasis

Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing an innovative pharmaceutical solution for the treatment of presbyopia symptoms, today announced the closing of a $30 million Series C financing. The financing was co-led by new investor Bluestem Capital and returning investor Visionary Ventures, with participation from other returning investors Sequoia Capital, SBI (Japan) Innovation Fund, Maverick Ventures, LifeSci Venture Partners and additional investors.